• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Safety and Therapeutic Effectiveness of Nonwashed Mediastinal Shed Blood Reinfused Into Patients Following Open Heart Surgery
【24h】

Safety and Therapeutic Effectiveness of Nonwashed Mediastinal Shed Blood Reinfused Into Patients Following Open Heart Surgery

机译：心脏直视手术后未经洗涤的纵隔血液再灌注患者的安全性和治疗效果

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This prospective study was designed to determine if use of nonwashed shed mediastinal blood could exacerbate platelet and related hematologic dysfunctions following cardiopulmonary bypass (CPB) when compared to the alternative use of autologous and homologous liquid preserved blood for volume support. Thirty-two patients undergoing CPB for open heart surgery were randomized to receive either nonwashed shed mediastinal (NSM) blood (Group 1, n = 16) or liquid preserved packed red blood cells (Group 2, n = 16) for transfusion (TXN) therapy of postoperative bleeding. Patient blood samples and bleeding times were obtained preoperatively, postCPB-preTXN, 2 and 24 hours postTXN, and on postoperative days 2, 3, and 7. Group 1 patients received an average of 710 +/- 90 ml (range 300-1700 ml) of NSM blood containing significantly greater (p < 0.0001) amounts of fibrin degradation products and D- dimer protein. Of the hematologic, microaggregate, and plasma protein measurements performed, only Protein C was significantly greater (p < 0.05, 1 vs. 2) after transfusion. Patient bleeding times were not significantly different between the groups at all time points. Total postoperative blood loss was not different between groups. There was a trend toward less need for homologous transfusion in Group 1 (p < 0.1). This study documents the safety, ease, and cost-saving of using nonwashed shed mediastinal blood as primary blood volume support following open heart surgery.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号